Patient Group Direction For the supply of Fusidic Acid 2% Cream
|
|
- Austin Osborne
- 5 years ago
- Views:
Transcription
1 Patient Group Direction For the supply of Fusidic Acid 2% Cream This Patient Group Direction (PGD) is a specific written instruction for the supply of Fusidic Acid 2% Cream to groups of patients who may not be individually identified before presentation for treatment. This will enable the appropriate registered healthcare professional to supply/administer treatment in accordance with the following protocol, the recommendations of the Department of Health 1998, the codes and standards of conduct of their professional bodies and any guidelines issues by those bodies on the supply and administration of medicines. The majority of clinical care should be provided on an individual, patient specific basis. The supply of medicines under Patient Group Directions should be reserved for those limited situations where this offers an advantage for patients care (without compromising patient safety) and where it is consistent with appropriate professional relationships and accountability. Definition of clinical situation/condition Name of organisation(s) within which the PGD will operate Name(s) of clinical areas and locations where the PGD will operate Criteria for inclusion For the treatment of localised lesions due to staphylococcal skin infections. (Impetigo) Community Pharmacies in NHS Tayside Adults and children aged 2 years or older presenting with minor skin infection limited to a few lesions in one area of the body (i.e. isolated lesions). The rash consists of vesicles that weep and then dry to form yellow-brown crusts (golden crusting with crusty scales and signs of infection). Must obtain parental/guardian consent for treating a child under the age of 16 years. Patient must be present at consultation. PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 1 of 12
2 Criteria for exclusion 1. Children under the age of 2 years. 2. Multiple skin site or widespread or bullous impetigo 3. Signs of systemic illness 4. Known hypersensitivity to any ingredients of the preparation (refer to patient information leaflet) 5. Had impetigo within the last 3 months 6. Patient refuses treatment 7. Presenting with any underlying skin condition on the same area of the body as impetigo 8. Concerns regarding patient compliance with topical medication. Action if excluded Action if patient declines Follow up of patient If exclusion refer to GP or OOH for further medical attention as appropriate Document advice given. Refer to own GP or OOH for review To GP if remains symptomatic after 7 days PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 2 of 12
3 Characteristics of staff authorised to take responsibility for the supply or administration of medicines under this patient group direction Qualifications Required Additional Requirements Continuing Training Requirements Profession Applicable professional codes and standards of conduct Applicable guidelines for supply and administration of medicines Pharmacist currently registered with the General Pharmaceutical Council GPhC. Must have undergone training in the use of PGDs and in the legal issues associated with prescribing medication under PGDs. The pharmacist must maintain their own level of competence and knowledge in this area to provide the service. They must also be familiar with the fusidic acid cream Summary of Product Characteristics. The pharmacist must undertake an antimicrobial/infection management CPD annually. Pharmacist The current GPhC Standards of Conduct, Ethics and Performance onduct-ethics-and-performance None, but guiding principles laid out in the above document. PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 3 of 12
4 DESCRIPTION OF TREATMENT AVAILABLE UNDER THIS PATIENT GROUP DIRECTION Name of Medicine POM/P/GSL PGD Ref No Dose/s Route Total dose number Duration Maximum or minimum treatment period Quantity to supply Advice to be given to the patient/carer Fusidic Acid 2% cream Prescription only medicine (POM) Apply thinly and evenly to affected area FOUR times daily for maximum of 7 days Topical Not more than four times daily Maximum treatment 7 days Use for a maximum of 7 days. Maximum of one supply in three months. 1 x 15g tube 1. Symptomatic improvement should be seen within a few days. Advise to seek further medical advice if no improvement in condition within 7 days. 2. Wash hands before and after applying cream. 3. Extended or recurrent application may increase the risk of contact sensitisation and the development of antibiotic resistance. 4. Successful treatment requires appropriate cleaning of the area failure to wash away the crust is a common cause of relapse. Advise crusting skin lesions should be softened by soaking in warm soapy water and where possible be removed prior to applying treatment. 5. Infection can be passed by direct contact with the lesion or through contaminated clothes or towels. Advise avoid sharing of towels, flannels etc until infection has gone. Change towels frequently to stop spread of infection and use a hot wash cycle for used towels. 6. Give advice on preventative measures to avoid reoccurrence of infection e.g. good personal hygiene, such as keeping PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 4 of 12
5 Identification and management of possible adverse effects Referral for medical advice Facilities and supplies required The designated hospital pharmacies OR fingernails clean and short. Do not scratch or pick spots. 7. As impetigo is easily transmitted, advise that the child should not go to nursery/school or adult to work until lesions are crusted or healed. Inform school of condition. 8. Do not share cream with anyone else. 9. Suggest applying cream three times daily on school days and four times at other times. 10. If the skin infection spreads or there is no improvement after 5 days, seek medical advice from GP. Inform of possible side effects and their management. Side effects with this product are rare however hypersensitivity reactions may occur For a full list of side effects refer to the marketing authorisation holder s Summary of Product Characteristics (SPC). A copy of the SPC must be available to the health professional administering medication under this Patient Group Direction. This can be accessed on All adverse reactions that are serious or result in harm should be reported to the MHRA through the Yellow Card Scheme. Occasionally patients may experience a local mild burning sensation following use. Patients/carers should be informed of who to contact should they experience an adverse drug reaction. See action if excluded information. Ensure patient/carer is aware that if symptoms worsen or the skin infection spreads then they should seek medical advice from their GP or through the OOH centre If symptoms have not improved after five days treatment, then patients should be advised to seek further medical advice. The medication will be supplied by the community pharmacy. PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 5 of 12
6 community pharmacy are the sole procurement point for medicines Treatment Records A treatment record sheet must be completed in all cases and signed and dated by the patient/carer and the pharmacist. In all cases a record of supply should be made on PMR which includes: Name, strength, form and pack size of medicine supplies Drug dose and route of administartion Date of supply and name of person making supply The medicine must be labelled in accordance with requirements detailed in the current in the current version of Medicines, Ethics and Practice. The patient s GP must be notified that a supply has taken place. The patient s GP must be informed if the patient experiences an adverse drug reaction Records of supply must be kept for 8 years. Patients on concurrent medication Patient Consent Audit Trail No known problems identified Informed consent will be obtained from the patient prior to treatment. The approved practitioner must ensure maintenance of records for each supply. The information relating to the supply of medication to each individual must include as a minimum Patient s name and date of birth Date given and by whom Date and details of communication with patients GP All records must be clear and legible, and ideally, in an easily retrievable format. This information should also be stored in the PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 6 of 12
7 individual s medication records. Adverse Reactions Any adverse events/incidents should be reported to the PGD group in addition to any existing pharmacy processes. Pharmacists should document and report all adverse incidents through their own internal governance systems or the NHS Tayside Datix system if available. All adverse reactions (actual and suspected) will be reported to the appropriate medical practitioner and recorded in the appropriate place. Pharmacist should record in their PMR and send and SBAR to the GP as appropriate. Where appropriate a Yellow Card Report will be forwarded to the Committee on Safety of Medicines. A supply of these forms can be found at the rear of the British National Formulary. Online reporting is available at AUDIT OF PATIENT GROUP DIRECTION Annual audit of documentation and recording of information - Who will carry this out and to whom will it be reported? Periodic audit of clinical outcome(s) - How often will audit be carried out? - What are the audit questions? - Who will carry out the audit(s) - To whom will the audit be reported? - To be carried out locally within each service - To be reported to Diane Robertson & Hazel Steele Audit will be carried out annually by the pharmacy. Data to be collected will include How many patients accessed this service? How many patients had antibiotics supplied? How many patients did not require fusidic acid? Any adverse events/incidents PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 7 of 12
8 MANAGEMENT & MONITORING OF PATIENT GROUP DIRECTION Developed By: Medical Practitioner: Dr Andrew Russell Pharmacist: Hazel Steele On Behalf of antimicrobial committee : Dr Busi Mooka Signature: Signature: Signature: Approved By: Dr Andrew Russell Lead Clinician Name: Dr Andrew Russell Signature: Tayside Area Drug & Therapeutics Committee Name: Professor Colin Fleming Signature: Date Effective: October 2017 Review Date: October 2019 Plans must be made to ensure completion of a review on or by the date above. The revised PGD will then follow on immediately. If the review date is reached and no review has taken place, then the PGD will be null and void. Interim review will be required as and when new safety information comes to light. PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 8 of 12
9 Declaration This protocol is authorised for use with (community pharmacy) by the individuals named below Pharmacist Date I have read and understood this PGD and have received the specified local training to implement it effectively. Name.. Designation... Signed. Date. Name.. Designation Signed. Date. Name.. Designation... Signed. Date. A copy of this agreement must be signed by each pharmacist who wishes to be authorised to use the PGD for Supply of Fusidic Acid 2% by Community Pharmacists working in Tayside Pharmacies. Please return this form (page 9) to The Pharmacy Department, East Day Home, Kings Cross Hospital, Clepington Road, Dundee DD3 8EA and retain a copy in each pharmacy premises they wish to provide the medicine from. A copy of the PGD must also be available in the pharmacy for reference. Each authorised pharmacy practitioner should be provided with an individual copy of the clinical content of the PGD and a photocopy of the document showing their authorisation. A complete register or practitioners authorised to use this PGD will be held by Diane Roberson, Community Pharmacy Development Pharmacist. PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 9 of 12
10 REGISTER OF NAMED INDIVIDUALS WHO MAY SUPPLY CARE UNDER THIS PATIENT GROUP DIRECTION Date Name Qualifications PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 10 of 12
11 PATIENT GROUP DIRECTION TREATMENT RECORD SHEET AMEND FROM HERE PHARMACY FIRST DOCUMENTATION A treatment record sheet is required for each patient treated under a Patient Group Direction Patient Group Direction Patient Record Proforma For The Supply Of Fusidic Acid 2% Cream Under Patient Group Direction 1. PATIENT AND CONSULTATION DETAILS Date of Consultation Patient Name CHI Place of Issue 2. PATIENT HISTORY AND EXAMINATION Does the patient present with symptoms Details of minor skin infections due to impetigo? 3. CRITERIA FOR INCLUSION The patient may receive care under this Patient Group Direction (PGD) if she/he presents with symptoms of a mild (singular lesions) minor skin infections due to impetigo and is aged 2 years of age or over. 4. CRITERIA FOR ABSOLUTE EXCLUSION The patient must be excluded from receiving treatment under this PGD, and referred to a medical practitioner as soon as possible, if one or more of the following criteria apply: Where the patient is less than two years of age Yes No The patient/carer requests to consult with a medical practitioner on this Yes No occasion The patient has uncertainty about the safety of Fusidic Acid 2% Cream Yes No despite counselling In so far as it can be ascertained the patient/carer has not given informed Yes No consent The patient has a known hypersensitivity to any ingredients of the Yes No preparation Where the patient has signs of widespread infection or systemic illness Yes No 5. CRITERIA FOR CAUTION If the patient is taking a medicine known to interact with Fusidic Acid 2% Cream 6. COUNSELLING Mode of action, efficacy and failure rate discussed? Yes No Method and manner of administration discussed? Yes No PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 11 of 12
12 Advise may experience a local mild burning sensation following use. Yes No Advise on cross infection, ease of transmission and reoccurrence Yes No Advise on follow up Yes No Issue written information Yes No 7. ACTION TAKEN Supply Fusidic Acid 2% Cream - Apply thinly and evenly to affected area to FOUR times daily for maximum of 7 days Batch number of Fusidic Acid 2% Cream supplied Expiry date of Fusidic Acid 2% Cream supplied Yes No Referred to: Referral Advice Given: 8. DECLARATION The above information is correct to the best of my knowledge. I have been counselled on the use of Fusidic Acid 2% Cream and understand the advice given to me by the practitioner. Patient s/carer s Signature: Date: The patient/carer is unable to give written consent. He/She has given verbal consent. Practitioner s Signature: Date: The action specified was based on the information given to me by the patient, which, to the best of my knowledge, is correct Practitioner s Signature: Date: PATIENT GROUP DIRECTION PATIENT INFORMATION SHEET A patient information sheet has to be given to each patient treated under a Patient Group Direction PGD Fusidic Acid 2% cream, Date Effective: October 2017 Page 12 of 12
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Date protocol prepared: October 2017 Date protocol due for review: October 2019 Expiry date: October
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 Date protocol prepared: December 2015 Date protocol due for review: December 2017 This patient group direction
More informationSupply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.
Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. November 2017 Review Nov 2019 Signatures of those developing the Patient Group
More informationNHS Lothian Patient Group Direction Version: 001
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% TO TREAT MINOR STAPHYLOCOCCAL SKIN INFECTIONS (IMPETIGO) IN PATIENTS AGED OVER 2 YEARS BY PHARMACISTS WORKING WITHIN NHS LOTHIAN COMMUNITY
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% FOR THE TREATMENT OF IMPETIGO BY COMMUNITY PHARMACISTS UNDER THE PHARMACY FIRST SERVICE IN NHS HIGHLAND THE COMMUNITY PHARMACIST SEEKING
More informationPatient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.
Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. This document authorises the supply of Fusidic Acid Cream 2% by registered
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationGG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationName Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019
PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed
More informationDocument Details. notification of entry onto webpage
Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As
More informationGG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) CO-CODAMOL 30/500 TABLETS FOR MINOR INJURIES UNITS Trust Ref No 1956-35206 Local Ref (optional) Main points the document treatment of moderate pain
More informationxrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY:
NHS FIFE PRIMARY CARE Patient Group Direction for Named Nurses in Contraception and Sexual Health Clinics to Supply Clotrim azole lo/o cream TO WOMEN CLIENTS for use in the treatment of vaginal candidiasis
More informationPatient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationTHE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS
PGD3717 PATIENT GROUP DIRECTION FOR THESUPPLY OF METRONIDAZOLE 400mg TABLETSFOR THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS (TV) by registered nurses and midwives in Integrated Sexual
More informationPATIENT GROUP DIRECTION (PGD) FOR
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPlease call the Pharmacy Medicines Unit on or for a copy.
Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This
More informationPATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationNon-Medical Prescribing Passport. Reflective Log And Information
Non-Medical Prescribing Passport Reflective Log And Information Non-Medical Prescribing Continued Profession Development Log NMPs must refer to their regulatory bodies requirements for maintaining and
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS Version 4 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse
More informationPatient Group Direction (PGD) template
Patient Group Direction (PGD) template Initial supply of doxycycline 100mg capsules to adults and children aged eight (8) years and over exposed to a suspected biological agent Version no: 2014/2 Valid
More informationGG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationPatient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian
NHS Grampian Patient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian Lead Author: Consultation Group: Approver: Highly
More informationPATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix )
PATIENT GROUP DIRECTION Administration of: By: Practice Nurses Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix ) In: General Practice It is the responsibility of the professional working
More informationNHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration)
GG&C PGD ref no: 2017/1523 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationUnlicensed Medicines Policy Document
Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale
More informationNon Medical Prescribing Policy Register No: Status: Public
Non Medical Prescribing Policy Policy Register No: 07049 Status: Public Developed in response to: Department of Health Policies, Prescribing Guidance & Legislation Contributes to CQC Outcome: 9 Consulted
More informationAppendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD)
Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD) PGD for the supply/administration of: Lidocaine 1% and Adrenaline 1:200,000 Master document reference number: This
More informationBest Practice Statement ~ March Patient Group Directions
Best Practice Statement ~ March 2006 Patient Group Directions NHS Quality Improvement Scotland 2005 ISBN 1-84404-403-3 First published March 2006 NHS Quality Improvement Scotland (NHS QIS) consents to
More informationName Job Title Signed Date
PGD3517 PATIENT GROUP DIRECTION FOR THE SUPPLY OF AZITHROMYCIN TABS/CAPS 250mg or TABS 500mg OR SUSPENSION 600mg/15mL FOR UNCOMPLICATED GENITAL CHLAMYDIA TRACHOMATIS, UNCOMPLICATED NEISSERIA GONORRHOEA
More informationBest Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers
Medicines Management in Care Homes Best Practice Guidance for GP Practices, Community Pharmacists and Care Home Providers 1. Communication The care home manager, community pharmacist and GP surgery should
More informationBest Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP
Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse
More informationCOMMUNITY PHARMACY MINOR AILMENTS SERVICE
COMMUNITY PHARMACY MINOR AILMENTS SERVICE SUPPORTING SELF-CARE OCTOBER 2010 CONTENTS Index Page No 1 Introduction 3 2 Service Specification 4 3 Consultation Procedure 7 4 Re-ordering Documentation 10 Appendices
More informationFOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING
STANDARD OPERATING PROCEDURE FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING Issue History Issue Version One Purpose of Issue/Description of Change To promote safe and effective medicine administration
More informationCompetencies and Training Framework
Community Pharmacy Enhanced Services Competencies and Training Framework Enhanced Service: Provision of Minor Ailments Service Level 1 (P & GSL medicines only) Level 2 (POMs, P & GSL) Version: Version
More informationAll areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final
Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy
More informationabcdefghijklmnopqrstu
NHS Circular: PCA (P)(2011) 6 Health and Healthcare Improvement Directorate Pharmacy and Medicines Division abcdefghijklmnopqrstu Dear Colleague ADDITIONAL PHARMACEUTICAL SERVICES MINOR AILMENT SERVICE
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP
More informationGuidance for registered pharmacies preparing unlicensed medicines
Guidance for registered pharmacies preparing unlicensed medicines May 2014 The text of this document (but not the logo and branding) may be reproduced free of charge in any format or medium, as long as
More informationConsultation Group: See relevant page in the PGD. Signature: 1. Review Date: November 2019
NHS...... Grampian Patient Group Direction For The Supply Of Aciclovir For The Treatment Of Herpes Zoster (Shingles) Infection By Banff Area Community Pharmacists Working Within NHS Grampian (Pilot Project)
More informationNHS GREATER GLASGOW AND CLYDE POLICIES RELATING TO THE MANAGEMENT OF MEDICINES SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION)
SECTION 9.1: UNLICENSED MEDICINES POLICY (ACUTE DIVISION) CONTENTS POLICY SUMMARY... 2 1. SCOPE... 4 2. AIM... 4 3. BACKGROUND... 4 4. POLICY STATEMENTS... 5 4.1. GENERAL STATEMENTS... 5 4.2 UNLICENSED
More informationPatient Group Direction Policy
Approval Process Patient Group Direction Policy Lead Author Developed by Sarah Woodley, Community Health Services Pharmacist 01223 474903 sarah.woodley@cambridgeshirepct.nhs.uk Sarah Woodley, Gillian Ascough,
More informationGROUP PROTOCOL FOR THE MANAGEMENT of HEARTBURN and ACID REFLUX. Version 4 January 2014
GROUP PROTOCOL FOR THE MANAGEMENT of HEARTBURN and ACID REFLUX Version 4 January 2014 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES January 2017 EXECUTIVE SPONSOR Executive
More informationPGDs are permitted for use only by registered health professionals (see enclosed link for full list
NHS England North - Yorkshire and the Humber Region Protocol for the Development, Authorisation and Use of Patient Group Directions for the National Immunisation Programmes 1. Introduction The preferred
More informationNational Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department
National Emergency Medicine Programme Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Date: November 2016 Table of Contents 1.0 Critical Elements... 3 2.0 Clinical
More informationPROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS
PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS Document Details Title Procedure for the administration of Homely Remedies in Community Hospitals Trust Ref No 1896-36344 Local
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationSFHPHARM29 - SQA Unit Code FA3A 04 Take a medication history
Overview This standard describes the skills, knowledge and understanding necessary to identify the prescribed and/or purchased medicines and other substances taken by an individual. The competence can
More informationNHS Lanarkshire Policy for the Availability of Unlicensed Medicines
NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:
More informationSection Title. Prescribing competency framework Catherine Picton, Lead author
Prescribing competency framework Catherine Picton, Lead author What is in this presentation Context Uses of the competency framework Scope of the updated prescribing competency framework Introduction to
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2016
Patient Group Direction For The Administration Of Adrenaline (Epinephrine) By Trained Nurses In The Management Of Cardiac Arrest In The Medical High Dependency Unit/Coronary Care Unit (MHDU/CCU) Working
More informationThe Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services
Standard Operating Procedure 2 (SOP 2) The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services Why we have a procedure? Black Country
More informationNHS Grampian Pharmaceutical Care Of Patients Receiving Treatment For Hepatitis C Service Specification
NHS Grampian Pharmaceutical Care Of Patients Receiving Treatment For Hepatitis C Service Specification 1. Service Objectives 1.1 The specific objectives of the service to provide pharmaceutical care to
More informationProcedure to Allow Nursing Staff to Dispense Leave and Discharge Medication
Procedure to Allow Nursing Staff to Dispense Leave and Discharge Medication Version 2 minor update June 2013 Procedure Number Replaces Policy No. Ratifying Committee N/a PPPF Date Ratified April 2009 Minor
More informationPromoting Effective Immunisation Practice
4th Edition 2017 Contents Introduction 3 Who is the programme for? 3 Learning Outcomes 4 Notes for employers 4 Updating 5 Notes for students 6 What are the options for learning? 6 Brief overview of the
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationTemplate (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment
Template (to be adapted by care home) Medication to be administered on a PRN (when required) basis in a care home environment The PRN Purpose & Outcome Protocol (PRN POP) Background The term PRN (from
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationCLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical
More informationIBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its
More informationSUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION
SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This
More informationDispensing Medications Practice Standard
October 2013 Updated December 8, 2016 s set out baseline requirements for specific aspects of Registered Psychiatric Nurses practice. They interact with other requirements such as the Code of Ethics, the
More informationPATIENT GROUP DIRECTION FOR AZITHROMYCIN
Staff Characteristics Pharmacist registered with the RPSGB who has undertaken relevant training as specified by NHS Bristol Has undertaken appropriate training to carry out clinical assessment of patient
More informationFundamentals of Self-Limiting Conditions Prescribing for Manitoba Pharmacists. Ronald F. Guse Registrar College of Pharmacists of Manitoba (CPhM)
Fundamentals of Self-Limiting Conditions Prescribing for Manitoba Pharmacists Ronald F. Guse Registrar College of Pharmacists of Manitoba (CPhM) 1 Learning Objectives Upon successful completion of this
More informationPARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
PARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its
More informationProcedure 26 Standard Operating Procedure for Controlled Drugs in homes within NHS Sutton CCG
Standard Operating Procedure for Controlled Drugs in homes within NHS Sutton CCG Introduction All health and social care organisations are accountable for ensuring the safe management of controlled drugs
More informationPatient Self Administration of Intravenous (IV) Antibiotics at Home
Trust Policy Document Ref. No: PP(16)319 Patient Self Administration of Intravenous (IV) Antibiotics at Home For use in: For use by: For use for: Document owner: Status: Clinical Areas Clinical Staff Patient
More informationPhotodynamic Therapy. Information for patients and carers
Photodynamic Therapy Information for patients and carers This leaflet aims to provide you with information on what you may experience with Photodynamic Therapy (PDT) and how to care for the area after
More informationManaging medicines in care homes
Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience
More informationThe Medicines Policy. Chapter 6: Standards of Practice. MISCELLANEOUS and DISCHARGE
Chapter 6: Standards of Practice MISCELLANEOUS and DISCHARGE V2.1 Date: October 2015 CHAPTER 6 CONTENTS 6.5. Miscellaneous... 3 6.5.1 Patients Moving Between Healthcare Trusts... 3 6.5.1.1 Transfer of
More informationNHS Rotherham CCG Medicines Management Team on behalf of NHS Rotherham CCG. Community Pharmacists in NHS Rotherham CCG
SERVICE LEVEL AGREEMENT TO ENABLE COMMUNITY PHARMACISTS IN NHS ROTHERHAM CLINICAL COMISSIONING GROUP TO SUPPLY TREATMENT AND ADVICE FOR MINOR AILMENTS PREPARED BY: NHS Rotherham CCG Medicines Management
More informationConsultation Group: See relevant page in the PGD. Review Date: October Expiry Date: October 2019
Patient Group Direction For The Administration Of Medicines Included In The Sepsis Formulary To Adults With Suspected Sepsis By Registered Nurses Working In Community Hospitals Within NHS Grampian Lead
More informationUnlicensed Medicines Policy
Who Should Read This Policy Target Audience All Consultant/Senior Medical Staff All Junior Medical Staff All Non-Medical Prescribers All Pharmacy Staff All Nursing Staff Version 1.0 February 2016 Ref.
More informationMedicines Management Strategy
Medicines Management Strategy 2012 2014 Directorate responsible for the strategy: Medical and Governance Directorate Staff group to whom it applies: All clinical staff and Trust managers Issue date: 30/6/12
More informationImproving compliance with oral methotrexate guidelines. Action for the NHS
Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication
More informationSocial care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1
Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:
More informationUnlicensed Medicines Policy
Unlicensed Medicines Policy This procedural document supersedes: PAT/MM 4 v.3 Policy and Procedure for the Use of Unlicensed Medicines Did you print this document yourself? The Trust discourages the retention
More informationAdministration of Medication Policy
St John s Catholic Primary School Administration of Medication Policy I have come that you may have life and have it to the full Roles and Responsibilities Parents/Carers (John 10:10) Have prime responsibility
More informationSupporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide
Supporting Self Care Choose Pharmacy Common Ailments Service GP Practice Guide Contents Section 1: Introduction Section 2: Service Information Section 3: Conditions to be Treated Section 4: Referrals &
More informationPROCEDURE FOR IMMUNISATION
Issue History Issue Version Purpose of Issue/Description of Change Planned Review Date One To promote the safe administration of vaccines 2014 Named Responsible Officer:- Approved by Date Medicines Governance
More informationMedicine Management Policy
INDEX Prescribing Page 2 Dispensing Page 3 Safe Administration Page 4 Problems & Errors Page 5 Self Administration Page 7 Safe Storage Page 8 Controlled Drugs Best Practice Procedure Page 9 Controlled
More informationSUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS
SUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS A Guide for Implementation within NHSScotland Scottish Executive Health Department SUPPLEMENTARY PRESCRIBING: PHARMACIST PRACTITIONERS A Guide for Implementation
More informationSELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING
CLINICAL PROTOCOL SELF - ADMINISTRATION OF MEDICINES AND ADMINISTRATION OF MEDICINES SUPPORTED BY FAMILY/INFORMAL CARERS OF PATIENTS IN COMMUNITY NURSING RATIONALE Medication errors can cause unnecessary
More informationThe Scottish Government
The Scottish Government Chief Nursing Officer Directorate Fiona McQueen, Chief Nursing Officer Dear Colleague Physiotherapist, Podiatrist or Independent Prescribing Services Summary Chiropodist The Scottish
More informationNON MEDICAL PRESCRIBING POLICY
NON MEDICAL PRESCRIBING POLICY Document Summary This Policy provides the framework and standards for Non-Medical Prescribing. The application of this policy will ensure that all non-medical prescribers
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2015
Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY PROCEDURE NUMBER Clinical.186 PROCEDURE VERSION 2 (Review). RATIFYING COMMITTEE Policy and Professional Practice Forum DATE RATIFIED 20 October 2015 DATE OF EQUALITY & September
More informationNHS Prescription Services CPAF Screening Questionnaire 2017/18
NHS Prescription Services CPAF Screening Questionnaire 207/8 Important Information about this Document This is a reference copy of the Community Pharmacy Assurance Framework Screening Questionnaire, the
More informationMedication Policy. Linked to National Quality Standards- Quality Area Two: Element Policy statement
Medication Policy Administering medication should be considered a high risk practice. Authority must be obtained from a parent or legal guardian before educators administer any medication (prescribed or
More informationDear Colleague. November 2013
NHS Circular: PCA (P) (2013) 29 ehealth, Finance & Pharmaceutical Directorate Pharmacy & Medicines Division Dear Colleague ADDITIONAL PHARMACEUTICAL SERVICES INTRODUCTION OF GLUTEN FREE FOOD SERVICE TIMETABLE,
More information